Literature DB >> 7489562

Splenectomy before tumor inoculation prolongs the survival time of cachectic mice.

K Soda1, M Kawakami, S Takagi, A Kashii, M Miyata.   

Abstract

The effects of splenectomy on the development of cachexia, tumor growth and animal survival were studied in tumor-bearing CDF1 mice. Mice were inoculated with two subclones of colon 26 adenocarcinoma, clone 20 (with a potent capacity to induce cachexia) and clone 5 (without such activity), and underwent splenectomy before or after tumor inoculation. Splenectomy significantly prolonged the survival of mice bearing clone 20 when it was performed prior to tumor inoculation, although the progression of cachexia and tumor growth were not affected. The survival rate was higher in splenectomized than it was in nonsplenectomized mice 20-40 days after tumor inoculation. Such effects on survival were not observed, however, in mice splenectomized after inoculation with clone 20 or in mice that underwent splenectomy either before or after inoculation with clone 5. The decrease of peripheral blood lymphocyte count observed in mice bearing clone 20 was magnified when splenectomy was performed before tumor inoculation, but the serum levels of tumor necrosis factor and interleukin-6 were comparable. These results indicate that cancer death from cachexia is not directly attributable to enhanced catabolism. The mechanism by which splenectomy ameliorates the survival of cachectic mice remains to be studied, although several changes observed in the splenectomized mice after inoculation, including decreases in the peripheral blood L3T4+ cells and Lyt-2+ cells on the 9th day and 15th day respectively, and increase in the L3T4+/Lyt-2+ cell ratio on the 15th day suggest the involvement of the modified host's immune response.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7489562     DOI: 10.1007/bf01516994

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  29 in total

1.  Changes of peripheral T-cell subsets in asplenic W256 tumor-bearing rats.

Authors:  Y G Ge; H Gao; X T Kong
Journal:  J Surg Oncol       Date:  1989-09       Impact factor: 3.454

Review 2.  Specificity in metabolic effects of cachectin/TNF and other related cytokines.

Authors:  M Kawakami; N Watanabe; H Ogawa; T Murase; N Yamada; H Sando; S Shibata; T Oda; F Takaku
Journal:  Ann N Y Acad Sci       Date:  1990       Impact factor: 5.691

3.  Purification of a lipoprotein lipase-inhibiting protein produced by a melanoma cell line associated with cancer cachexia.

Authors:  M Mori; K Yamaguchi; K Abe
Journal:  Biochem Biophys Res Commun       Date:  1989-05-15       Impact factor: 3.575

Review 4.  Postsplenectomy sepsis and its mortality rate: actual versus perceived risks.

Authors:  R J Holdsworth; A D Irving; A Cuschieri
Journal:  Br J Surg       Date:  1991-09       Impact factor: 6.939

5.  The roles of gamma-interferon and tumor necrosis factor alpha in an experimental rat model of cancer cachexia.

Authors:  H N Langstein; G M Doherty; D L Fraker; C M Buresh; J A Norton
Journal:  Cancer Res       Date:  1991-05-01       Impact factor: 12.701

6.  Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group.

Authors:  W D Dewys; C Begg; P T Lavin; P R Band; J M Bennett; J R Bertino; M H Cohen; H O Douglass; P F Engstrom; E Z Ezdinli; J Horton; G J Johnson; C G Moertel; M M Oken; C Perlia; C Rosenbaum; M N Silverstein; R T Skeel; R W Sponzo; D C Tormey
Journal:  Am J Med       Date:  1980-10       Impact factor: 4.965

7.  Tumors secreting human TNF/cachectin induce cachexia in mice.

Authors:  A Oliff; D Defeo-Jones; M Boyer; D Martinez; D Kiefer; G Vuocolo; A Wolfe; S H Socher
Journal:  Cell       Date:  1987-08-14       Impact factor: 41.582

8.  Manifestations of cancer cachexia induced by colon 26 adenocarcinoma are not fully ascribable to interleukin-6.

Authors:  K Soda; M Kawakami; A Kashii; M Miyata
Journal:  Int J Cancer       Date:  1995-07-28       Impact factor: 7.396

9.  The spleen can influence the metastasis of AH130 hepatoma cells in rats.

Authors:  M Toyonaga; T Hiraoka; H Tanaka; Y Miyauchi
Journal:  J Surg Oncol       Date:  1993-06       Impact factor: 3.454

10.  Characterization of mice bearing subclones of colon 26 adenocarcinoma disqualifies interleukin-6 as the sole inducer of cachexia.

Authors:  K Soda; M Kawakami; A Kashii; M Miyata
Journal:  Jpn J Cancer Res       Date:  1994-11
View more
  4 in total

1.  Expanding spectrum of the association between Type 1 Gaucher disease and cancers: a series of patients with up to 3 sequential cancers of multiple types--correlation with genotype and phenotype.

Authors:  Sarah M Lo; Philip Stein; Sean Mullaly; Michael Bar; Dhanpat Jain; Gregory M Pastores; Pramod K Mistry
Journal:  Am J Hematol       Date:  2010-05       Impact factor: 10.047

2.  Long-term risks after splenectomy among 8,149 cancer-free American veterans: a cohort study with up to 27 years follow-up.

Authors:  Sigurdur Y Kristinsson; Gloria Gridley; Robert N Hoover; David Check; Ola Landgren
Journal:  Haematologica       Date:  2013-09-20       Impact factor: 9.941

3.  Splenectomy inhibits non-small cell lung cancer growth by modulating anti-tumor adaptive and innate immune response.

Authors:  Liran Levy; Inbal Mishalian; Rachel Bayuch; Lida Zolotarov; Janna Michaeli; Zvi G Fridlender
Journal:  Oncoimmunology       Date:  2015-01-22       Impact factor: 8.110

4.  Myeloid PTEN deficiency impairs tumor-immune surveillance via immune-checkpoint inhibition.

Authors:  M Kuttke; E Sahin; J Pisoni; S Percig; A Vogel; D Kraemmer; L Hanzl; J S Brunner; H Paar; K Soukup; A Halfmann; A M Dohnal; C W Steiner; S Blüml; J Basilio; B Hochreiter; M Salzmann; B Hoesel; G Lametschwandtner; R Eferl; J A Schmid; G Schabbauer
Journal:  Oncoimmunology       Date:  2016-03-28       Impact factor: 7.723

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.